Adverse events	Orlistat	Sibutramine	Fluoxetine
Gastrointestinal	Minor GI events: range 65% to 80% I, 27% to 62% C , most mild to moderate, transient (Hollander 1998, Lindgarde 2000, Kelley 2002, Miles 2002, Shi 2001, Halpern 2003, Hanefeld 2002, Kelley 2004) 34% GI effects (Allie 2004)	Minor Constipation: 9% to 55% I, 6% to 8% C(Gokcel 2001, Fujioka 2000, Serrano‐Rios 2002, Chaisson 1989); 4% (Tankova 2003)	Minor Various: NSD between I and C(Connolly 1995) Nausea: range 15% to 35% I, 6% to 20% C(Daubresse 1996, Kutnowski 1992, Chaisson 1989) Diarrhea: 6% I, 2% C (p>0.05)(Daubresse 1996); 8% I, 4% C (p>0.05)(Gray 1992) Anorexia: 12% I, 3% C (p<0.05)(Chaisson 1989) Nausea, vomiting, diarrhea: 66% I, 60% C(O'Kane 1994)
Cardiovascular		Major Rhythm disturbances: NSD between groups(Finer 1994) Chest pain not suggestive of angina: 7% (2/27)(Sircar 2001) Palpitations (moderate to severe): 41% I, 29% C(Serrano‐rios 2002) Minor Increased pulse rate: mean 2.4 beats/minute I (p>0.05)(Serrano‐Rios 2002); mean 6 beats/minute I (p<0.01) (McNulty 2003) Increased systolic blood pressure (4 mmHg) and diastolic blood pressure (3 mmHg) in 15mg qd group; systolic blood pressure >=10 mmHG higher at endpont than baseline in 36% and 29% of patients receiving 15 and 20 mg (MuNulty 2003) Palpitations: 7.4% I(Chaisson 1989)
Neurologic		Minor Headache: 22% to 32% I, 40% C(Finer 2000, Sircir 2001) Dizziness: 9 to 14% I, 5% to 13% C(Finer 2000, Sircir 2001) Anxiety: 9% I, 0% C(Serrano‐Rios 2002) Sleeplessness: 7% (Tankova 2003)	Minor Tremor: 5% to 15% I, 0% to 3% C(Daubresse 1996, Kutnowski 1992, Chaisson 1989, Wise 1989) Somnolence: 11% to 22% I, 4% to 7% C(Daubresse 1996, Chaisson 1989) Headache: 13% I, 8% C(Gray 1992) Asthenia: 37% I, 20% C (p>0.05)(Chaisson 1989) Sweating: 28% I, 11% C (p<0.05)(Chaisson 1989) Abnormal dreams: 12% I, 4% C (p<0.05)(Chaisson 1989) Sweating, somnolence, nausea, tremor, anorexia: I > C(no statistics) (Goldstein 1992)
Withdrawal due to adverse effects	Minor Various: 13% I, 8% C (Kelley 2002); 10% I, 5% C (p<0.05)(Miles 2002) Deterioration in glycemic control: 15% I, 28% C(Kelley 2002) GI: 4.3% I, 1.2% C(Hollander 1998); 2.6% I, 0.5% C(Lindgarde 2000); 4.7% I, 2.9% C(Halpern 2003); 0.3% I(Shi 2001); 13% I, NR for C (Kelley 2004) 22% I (Allie 2004)	Major Palpitations: 3% I, 0% C(Serrano‐Rios 2002) Hypertension: 3% (one patient) developed (Gokcel 2001) Minor Insomnia, nervousness: 6% (Redmon 2003) Dizziness, insomnia, or diarrhea: 7% I(Finer 2000) Chest pain not suggestive of angina: 4% I(Sircar 2001) Dizziness, hyperglycemia, nausea: 3% I(Fukuika 2000)	Major Chest pain: 8% I, 0% C (p>0.05)(Gray 1992) Minor GI: 22%(O'Kane 1994) Nausea, lethargy, or excessive sweating: 20%(Connolly 1995) Unspecified: 1% to 9% I, 1% to 2% C (Daubresse 1996, Kutnowski 1992) Connolly 1995)
Other	Minor Hypoglycemia: 7% to 17% I, 3% to 10% C(Kelley 2002, Miles 2002, Hanfeld 2002) No gallstones, no renal stones(Hollander 1998) Normal plasma concentrations vitamin A,D,E, beta‐carotene(Hollander 1998) Decrease in vitamin E and beta‐carotene concentrations in I vs C (p<0.001)(Hollander 1998) No significant difference in adverse events I and C (p=0.75)(Serrano‐rios 2001)	Major Serious AE: 6% I, 1% C (1/ 5 in I possibly drug‐related (somnolence, dizziness, confusion)) (Fujioka 2000) Minor Dry mouth: 38% I, NR C(Gokcel 2001); 23% I, 11% C(Finer 2000); "common"(McNulty 2003); reported in Redmon 2003 (no data); 6% (Tankova 2003) Infection (not specified): 18% to 26% I, 2% to 24% C(Finer 2000, Fujioka 2000) Increased platelet count and increased serum sodium in I (Serrano‐Rios 2002) AE unspecified: 61% I, 52% C(Serrano‐Rios 2002)	Minor Infections: 50% I, 55% C(Breum 1995); NSD between groups(Connolly 1995) Decreased libido: 13% I, 0% C (p=0.07)(Gray 1992)